ArticleEcotoxicology and environmental safety2025
Perfluorooctanesulfonamide-induced epiboly delay is associated with decreased ATP production within zebrafish embryos.
Article in Ecotoxicology and environmental safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Per- and polyfluoroalkyl substances (PFAS) persistence within environmental media has led to ubiquitous exposure within humans and wildlife. We previously found that exposure of zebrafish embryos to perfluorooctanesulfonamide (PFOSA) from 0.75 to 6 h post-fertilization (hpf) resulted in a concentration-dependent delay in epiboly - a critical developmental landmark in fish and amphibian species. Therefore, for this study, we explored whether 1) similar mechanisms underlie epiboly delays induced by PFOSA or Cytochalasin B (CCB), a potent inhibitor of actin polymerization that disrupts normal epiboly progression, and 2) PFOSA-induced epiboly delay is associated with a decrease in embryonic ATP, as PFOSA is a potent uncoupler of oxidative phosphorylation in vitro. Although PFOSA and CCB induced a similar magnitude of epiboly delay beginning at 4 hpf following initiation of exposure at 0.75 hpf, PFOSA did not, contrary to CCB, significantly decrease yolk-associated actin within embryos. Using mRNA-sequencing, we also found that, consistent with chemical-specific differences in effects on actin polymerization, PFOSA-exposed embryos were also transcriptionally different from CCB-exposed embryos. Moreover, phenotypically matched, PFOSA-exposed embryos at 6 hpf were transcriptionally similar to vehicle-exposed embryos at 5 hpf, and PFOSA delayed the maternal-to-zygotic transition (MZT) beginning at 5 hpf. Finally, PFOSA-induced delayed epiboly was associated with decreased ATP concentrations, an effect that was partially mitigated by co-exposure to exogenous ATP. Overall, our findings suggest that PFOSA exposure during early embryonic development decreases ATP production in the absence of effects on actin polymerization in vivo, an effect that is associated with PFOSA-induced delays in epiboly and the MZT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.